Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report
- 1University Hospital Southampton National Health Service Foundation Trust, Southampton, UK
Abstract
Introduction. Candidozyma auris is an emerging multidrug-resistant fungal pathogen associated with healthcare outbreaks and significant mortality. Management can be challenging due to antifungal resistance and the need for prolonged intravenous therapy.
Case Presentation. A 58-year-old man developed a postoperative sternal wound infection caused by multidrug-resistant C. auris following aortic valve replacement, coronary artery bypass grafting and ascending aortic interposition graft surgery. His postoperative course was complicated by Staphylococcus epidermidis prosthetic graft infection requiring redo valve replacement and graft repair and placement of vacuum-assisted closure. Two weeks after discharge home, persistent wound discharge yielded C. auris. Following surgical debridement and initiation of intravenous caspofungin with oral itraconazole, once-daily intravenous antifungal therapy was transitioned to once-weekly intravenous rezafungin to facilitate outpatient treatment coordinated with vacuum-assisted wound therapy.
Conclusion. After 12 weeks of dual antifungal therapy, complete clinical and microbiological resolution was achieved without adverse events. This case highlights the feasibility of rezafungin as an outpatient treatment strategy for complex multidrug-resistant C. auris infections.
Related
- Candidozyma auris (formerly Candida auris): A P6 medicine framework integrating genomics, surveillance and the prevention of multidrug-resistant fungal threats.
- Immune dysregulation: an “accelerator” of gut resistome expansion and multidrug-resistant organism infection risk in ICU patients
- A High-Energy Military Femoral Fracture With Multidrug-Resistant Infection: A Case Report.
- Probable primary bloodstream infection caused by multidrug-resistant Achromobacter piechaudii in an apparently immunocompetent child: a case report
- Case Report: Herbal nutritional intervention in a critically ill ALS patient with multidrug-resistant infection.
BibTeX
@article{luthra2026rezafungin,
title = {{Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report}},
author = {Suvitesh Luthra and Annette David and David Thirukumaran and Tat Shing Yam},
journal = {Access Microbiology},
year = {2026},
month = nov,
doi = {10.1099/acmi.0.001171.v4},
url = {https://doi.org/10.1099/acmi.0.001171.v4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rezafungin for sternal wound infection caused by multidrug-resistant Candidozyma auris: a case report
AU - Suvitesh Luthra
AU - Annette David
AU - David Thirukumaran
AU - Tat Shing Yam
PY - 2026
DA - 2026/11/12
JO - Access Microbiology
DO - 10.1099/acmi.0.001171.v4
UR - https://doi.org/10.1099/acmi.0.001171.v4
AB - Introduction. Candidozyma auris is an emerging multidrug-resistant fungal pathogen associated with healthcare outbreaks and significant mortality. Management can be challenging due to antifungal resistance and the need for prolonged intravenous therapy. Case Presentation. A 58-year-old man developed a postoperative sternal wound infection caused by multidrug-resistant C. auris following aortic valve replacement, coronary artery bypass grafting and ascending aortic interposition graft surgery. His postoperative course was complicated by Staphylococcus epidermidis prosthetic graft infection requiring redo valve replacement and graft repair and placement of vacuum-assisted closure. Two weeks after discharge home, persistent wound discharge yielded C. auris. Following surgical debridement and initiation of intravenous caspofungin with oral itraconazole, once-daily intravenous antifungal therapy was transitioned to once-weekly intravenous rezafungin to facilitate outpatient treatment coordinated with vacuum-assisted wound therapy. Conclusion. After 12 weeks of dual antifungal therapy, complete clinical and microbiological resolution was achieved without adverse events. This case highlights the feasibility of rezafungin as an outpatient treatment strategy for complex multidrug-resistant C. auris infections.
SN - 2516-8290
ER -